MARKET

SAVA

SAVA

Cassava Sciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

34.85
-0.24
-0.68%
After Hours: 34.99 +0.14 +0.40% 19:39 04/16 EDT
OPEN
34.65
PREV CLOSE
35.09
HIGH
35.33
LOW
33.68
VOLUME
1.03M
TURNOVER
--
52 WEEK HIGH
117.54
52 WEEK LOW
1.630
MARKET CAP
1.39B
P/E (TTM)
-147.1706
1D
5D
1M
3M
1Y
5Y
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $34.85, marking a -0.68% move from the previous day.
Zacks · 2d ago
Cassava Sciences Granted U.S. Patent Application Titled 'METHOD OF INHIBITING TAU PHOSPHORYLATION'
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=2&f=G&l=50&d=PG01&p=1&S1=alzheimers&OS=alzheimers&RS=alzheimers
Benzinga · 04/01 14:54
Top Health Care Stocks Worth Investing In Now? 4 In Focus
Mar 26, 2021 (StockMarket.com via COMTEX) -- Are These The Best Health Care Stocks To Buy Before April 2021? No matter the state of the world, the health...
StockMarket.com · 03/26 12:54
Has Cassava Sciences (SAVA) Outpaced Other Medical Stocks This Year?
Zacks.com · 03/24 18:34
10-K: CASSAVA SCIENCES INC
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations This discussion and analysis...
Edgar Online - (EDG = 10Q, 10K) · 03/23 21:08
BRIEF-Cassava Sciences Announces Full-Year 2020 Financial Results
reuters.com · 03/23 13:38
Cassava Sciences EPS misses by $0.04
Cassava Sciences (SAVA): Q4 GAAP EPS of -$0.09 misses by $0.04.Cash and cash equivalents of $93.5MPress Release
Seekingalpha · 03/23 13:28
Cassava Sciences Says Plans To Initiate A Randomized, Placebo-Controlled Cognition Maintenance Study In Alzheimer's Disease
 Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced financial results for the year ended December 31, 2020 and provided business updates.
Benzinga · 03/23 12:39
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SAVA. Analyze the recent business situations of Cassava Sciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SAVA stock price target is 77.75 with a high estimate of 110.00 and a low estimate of 24.00.
EPS
Institutional Holdings
Institutions: 97
Institutional Holdings: 11.85M
% Owned: 29.71%
Shares Outstanding: 39.90M
TypeInstitutionsShares
Increased
35
2.84M
New
19
1.67M
Decreased
13
914.45K
Sold Out
9
353.43K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Director/President/Chief Executive Officer
Remi Barbier
Chief Financial Officer
Eric Schoen
Chief Operating Officer/Director
Nadav Friedmann
Other
James Kupiec
Independent Director
Robert Gussin
Independent Director
Michael O' Donnell
Independent Director
Sanford Robertson
Independent Director
Patrick Scannon
Declaration Date
Dividend Per Share
Ex-Div Date
12/07/2012
Dividend USD 0.75
12/13/2012
10/25/2010
Dividend USD 2
12/13/2010
  • All
  • Financials
  • Insiders
More
About SAVA
Cassava Sciences, Inc., formerly Pain Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing drug for the treatment of nervous system disorders. The Company is ocused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer’s. Its drug candidate, PTI-125, is a small molecule that targets an altered form of a scaffolding protein called filamin A (FLNA). The Company is also developing an experimental biomarker/diagnostic, PTI-125Dx. It is developing PTI-125Dx to detect Alzheimer’s disease with a blood test.

Webull offers kinds of Cassava Sciences Inc stock information, including NASDAQ:SAVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SAVA stock methods without spending real money on the virtual paper trading platform.